BiotechTube

Non-selective NSAIDS + Celecoxib

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ankle Sprain

Conditions

Ankle Sprain

Trial Timeline

May 1, 2007 → Apr 1, 2008

NCT ID
NCT00446797

About Non-selective NSAIDS + Celecoxib

Non-selective NSAIDS + Celecoxib is a approved stage product being developed by Pfizer for Ankle Sprain. The current trial status is completed. This product is registered under clinical trial identifier NCT00446797. Target conditions include Ankle Sprain.

What happened to similar drugs?

2 of 6 similar drugs in Ankle Sprain were approved

Approved (2) Terminated (0) Active (4)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅diclofenac potassium 25 mg tablet + placeboNovartisApproved
🔄Diclofenac SodiumNovartisPhase 3
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
🔄Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
🔄Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00446797ApprovedCompleted

Competing Products

7 competing products in Ankle Sprain

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
diclofenac potassium 25 mg tablet + placeboNovartisApproved
43
Diclofenac SodiumNovartisPhase 3
40
Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / PlaceboNovartisPhase 2
35
diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
40
Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
40
Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3
40